$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

$lsta Overview Financials Valuation SEC Filings Company Website

2012 Q4 Form 10-Q Financial Statement

#000032001712000019 Filed on November 13, 2012

Income Statement

Concept	2012 Q4	2012 Q3	2011 Q3
Revenue	$2.750M	$4.434M	$2.177M
YoY Change	-34.68%	103.67%	-86.79%
Cost Of Revenue	$2.550M	$3.747M	$1.891M
YoY Change	-22.96%	98.14%	-83.16%
Gross Profit	$200.0K	$686.5K	$285.7K
YoY Change	-77.78%	140.29%	-94.55%
Gross Profit Margin	7.27%	15.48%	13.12%
Selling, General & Admin	$5.180M	$5.947M	$5.976M
YoY Change	-18.94%	-0.48%	-35.81%
% of Gross Profit	2590.0%	866.35%	2091.75%
Research & Development	$2.950M	$2.828M	$1.540M
YoY Change	43.2%	83.6%	-8.31%
% of Gross Profit	1475.0%	411.99%	539.22%
Depreciation & Amortization	$390.0K	$390.0K	$300.0K
YoY Change	77.27%	30.0%	-72.48%
% of Gross Profit	195.0%	56.81%	105.01%
Operating Expenses	$8.140M	$8.775M	$7.516M
YoY Change	-3.78%	16.76%	-31.61%
Operating Profit	-$7.940M	-$8.089M	-$7.230M
YoY Change	5.03%	11.87%	25.75%
Interest Expense	-$220.0K	$384.2K	$632.8K
YoY Change	-62.71%	-39.29%	-6428.37%
% of Operating Profit
Other Income/Expense, Net	-$4.350M	-$459.0K	$660.1K
YoY Change	-952.94%	-169.55%	1220.15%
Pretax Income	-$12.51M	-$8.548M	-$6.570M
YoY Change	63.96%	30.11%	15.06%
Income Tax	-$180.0K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$15.51M	-$8.411M	-$7.346M
YoY Change	-17.72%	14.49%	2.89%
Net Earnings / Revenue	-564.0%	-189.69%	-337.45%
Basic Earnings Per Share
Diluted Earnings Per Share	-$9.755M	-$5.682M	-$7.819M
COMMON SHARES
Basic Shares Outstanding	159.4M shares	152.5M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2012 Q4	2012 Q3	2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.70M	$5.400M	$11.70M
YoY Change	251.28%	-53.85%	172.09%
Cash & Equivalents	$12.30M	$5.391M	$10.16M
Short-Term Investments			$0.00
Other Short-Term Assets	$1.900M	$40.20M	$3.800M
YoY Change	-94.24%	957.89%	-19.15%
Inventory	$1.113M	$448.0K	$20.60M
Prepaid Expenses
Receivables	$1.054M	$1.795M	$8.900M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$16.71M	$47.89M	$45.10M
YoY Change	-56.73%	6.18%	59.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.15M	$11.07M	$49.60M
YoY Change	-3.99%	-77.69%	49.4%
Goodwill	$11.12M	$11.12M
YoY Change	0.0%
Intangibles	$14.48M	$14.63M
YoY Change	-4.01%
Long-Term Investments
YoY Change
Other Assets	$947.3K	$932.5K	$5.600M
YoY Change	-71.53%	-83.35%	1300.0%
Total Long-Term Assets	$37.70M	$80.92M	$123.1M
YoY Change	-67.7%	-34.26%	38.78%
TOTAL ASSETS
Total Short-Term Assets	$16.71M	$47.89M	$45.10M
Total Long-Term Assets	$37.70M	$80.92M	$123.1M
Total Assets	$54.41M	$128.8M	$168.2M
YoY Change	-64.97%	-23.42%	43.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.555M	$2.571M	$9.900M
YoY Change	11.72%	-74.03%	30.26%
Accrued Expenses	$2.285M	$1.386M	$5.900M
YoY Change	109.58%	-76.52%	25.53%
Deferred Revenue
YoY Change
Short-Term Debt	$3.400M	$3.500M	$8.000M
YoY Change	-5.56%	-56.25%
Long-Term Debt Due	$200.0K	$100.0K	$3.800M
YoY Change	100.0%	-97.37%	-41.54%
Total Short-Term Liabilities	$9.949M	$50.44M	$31.50M
YoY Change	-72.7%	60.11%	52.91%
LONG-TERM LIABILITIES
Long-Term Debt	$200.0K	$2.800M	$5.500M
YoY Change	-95.83%	-49.09%
Other Long-Term Liabilities	$214.9K	$139.3K	$25.10M
YoY Change		-99.45%	202.41%
Total Long-Term Liabilities	$21.59M	$21.94M	$30.60M
YoY Change	-36.39%	-28.29%	268.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.949M	$50.44M	$31.50M
Total Long-Term Liabilities	$21.59M	$21.94M	$30.60M
Total Liabilities	$31.54M	$72.38M	$94.70M
YoY Change	-55.19%	-23.57%	32.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$197.4M	-$181.6M
YoY Change	37.95%
Common Stock	$16.38K	$155.1K
YoY Change	-85.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$665.6K
YoY Change
Treasury Stock Shares	104.0K shares
Shareholders Equity	$33.18M	$48.21M	$73.60M
YoY Change
Total Liabilities & Shareholders Equity	$54.41M	$128.8M	$168.2M
YoY Change	-64.97%	-23.42%	43.76%

Cashflow Statement

Concept	2012 Q4	2012 Q3	2011 Q3
OPERATING ACTIVITIES
Net Income	-$15.51M	-$8.411M	-$7.346M
YoY Change	-17.72%	14.49%	2.89%
Depreciation, Depletion And Amortization	$390.0K	$390.0K	$300.0K
YoY Change	77.27%	30.0%	-72.48%
Cash From Operating Activities	-$9.620M	-$3.380M	-$4.250M
YoY Change	182.11%	-20.47%	-1617.86%
INVESTING ACTIVITIES
Capital Expenditures	-$330.0K	-$20.00K	-$120.0K
YoY Change	450.0%	-83.33%	-96.91%
Acquisitions
YoY Change
Other Investing Activities	$9.110M	-$350.0K	$3.410M
YoY Change	699.12%	-110.26%	283.15%
Cash From Investing Activities	$8.780M	-$370.0K	$3.290M
YoY Change	712.96%	-111.25%	-210.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.680M	1.690M	7.670M
YoY Change	-147.32%	-77.97%	-282.19%
NET CHANGE
Cash From Operating Activities	-9.620M	-3.380M	-4.250M
Cash From Investing Activities	8.780M	-370.0K	3.290M
Cash From Financing Activities	-1.680M	1.690M	7.670M
Net Change In Cash	-2.520M	-2.060M	6.710M
YoY Change	-306.56%	-130.7%	-196.97%
FREE CASH FLOW
Cash From Operating Activities	-$9.620M	-$3.380M	-$4.250M
Capital Expenditures	-$330.0K	-$20.00K	-$120.0K
Free Cash Flow	-$9.290M	-$3.360M	-$4.130M
YoY Change	177.31%	-18.64%	-199.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1916200	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8164800	USD
CY2012Q3	us-gaap	Assets Current AssetsCurrent	47886255	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	38610336	USD
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2287201	USD
CY2012Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2570879	USD
CY2012Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1794579	USD
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1010475	USD
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1090176	USD
CY2012Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1385510	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4152343	USD
CY2012Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4148767	USD
CY2012Q2	us-gaap	Additional Information About Entitys Reportable Segments AdditionalInformationAboutEntitysReportableSegments	three reportable segments
CY2012Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	225528652	USD
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	200858638	USD
CY2011Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1507800	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5471200	USD
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	187600	USD
CY2012Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	442302	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1195217	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1903703	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	591200	USD
CY2012Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	151300	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	453900	USD
CY2011Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	211300	USD
CY2012Q3	us-gaap	Assets Assets	128806060	USD
CY2011Q4	us-gaap	Assets Assets	155327780	USD
CY2011Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	32367217	USD
CY2012Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	37024245	USD
CY2011Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Noncurrent AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	75570645	USD
CY2012Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Noncurrent AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	43169861	USD
CY2011Q4	us-gaap	Business Acquisition Contingent Consideration At Fair Value Noncurrent BusinessAcquisitionContingentConsiderationAtFairValueNoncurrent	3130000	USD
CY2012Q3	us-gaap	Business Acquisition Contingent Consideration At Fair Value Noncurrent BusinessAcquisitionContingentConsiderationAtFairValueNoncurrent	3130000	USD
CY2012Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	600000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	227942	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3935160	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5390611	USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10164987	USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	11713338	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	12745432	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	16180091	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	15612391	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3899053	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3434659	USD
CY2011Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	800000	USD
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-5198330	USD
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-1390641	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-5218531	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-2848309	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-1562004	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	12168199	USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	7950107	shares
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	109329587	shares
CY2012Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	155141086	shares
CY2012Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	155141086	shares
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	109329587	shares
CY2012Q3	us-gaap	Common Stock Value CommonStockValue	155141	USD
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	109330	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27115302	USD
CY2011Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4488971	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-38267957	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8436474	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-9611	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-12610486	USD
CY2011Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-705130	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	1609135	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-25506167	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-8446085	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-50878443	USD
CY2011Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-5194101	USD
CY2012Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1	shares
CY2011Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1	shares
	us-gaap	Cost Of Revenue CostOfRevenue	9439185	USD
	us-gaap	Cost Of Revenue CostOfRevenue	5336079	USD
CY2011Q3	us-gaap	Cost Of Revenue CostOfRevenue	1891334	USD
CY2012Q3	us-gaap	Cost Of Revenue CostOfRevenue	3747490	USD
CY2012Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	778088	USD
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1121134	USD
CY2012Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	143734	USD
CY2011Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	169198	USD
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25994800	USD
CY2012Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	3774655	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	3774655	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1221346	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1160596	USD
CY2012Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	427553	USD
CY2011Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	474463	USD
CY2012Q3	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	10789480	USD
CY2011Q3	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	1548351	USD
	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-248294	USD
CY2011Q3	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-35222	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-8548052	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-23765160	USD
CY2011Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-6570376	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2011Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	234756	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-72136	USD
CY2009Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.51
CY2012Q2	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.51
CY2012Q3	us-gaap	Fair Value Liabilities Measured On Recurring Basis Debt Instrument Valuation Techniques FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniques	The fair value of contingent consideration obligations is based on a discounted cash flow model using a probability-weighted income approach
CY2012Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1136900	USD
CY2011Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	683000	USD
CY2011Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15769000	USD
CY2012Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15769000	USD
CY2012Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14632100	USD
CY2011Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	15086000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-12964	USD
CY2012Q3	us-gaap	Goodwill Goodwill	11117770	USD
CY2011Q4	us-gaap	Goodwill Goodwill	11117770	USD
	us-gaap	Gross Profit GrossProfit	2139598	USD
CY2011Q3	us-gaap	Gross Profit GrossProfit	285679	USD
CY2012Q3	us-gaap	Gross Profit GrossProfit	686471	USD
	us-gaap	Gross Profit GrossProfit	500899	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-23516866	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-26699496	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-8488480	USD
CY2011Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-6535154	USD
	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-237127	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-59572	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-26936623	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.06
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.32
CY2011Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.07
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.18
CY2011Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-758088	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-792113	USD
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	152095	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-27260584	USD
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	74524	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	-12513069	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	796206	USD
CY2011Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	53193	USD
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	77571	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1588319	USD
CY2011Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-811281	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-14747515	USD
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.00
CY2011Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.01
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.02
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.11
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1841400	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1463100	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	944206	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1112107	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-159900	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-368510	USD
CY2011Q3	us-gaap	Increase Decrease In Fair Value Of Interest Rate Fair Value Hedging Instruments IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments	70800	USD
CY2012Q3	us-gaap	Increase Decrease In Fair Value Of Interest Rate Fair Value Hedging Instruments IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments	-6200	USD
	us-gaap	Increase Decrease In Fair Value Of Interest Rate Fair Value Hedging Instruments IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments	-134800	USD
	us-gaap	Increase Decrease In Fair Value Of Interest Rate Fair Value Hedging Instruments IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments	87900	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-779043	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-199700	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-125489	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	187123	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4337	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	223527	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	752	USD
CY2012Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	14632130	USD
CY2011Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	15086038	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	36924	USD
	us-gaap	Interest Expense InterestExpense	1359187	USD
	us-gaap	Interest Paid InterestPaid	1655600	USD
CY2011Q3	us-gaap	Interest Expense InterestExpense	632837	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	384168	USD
	us-gaap	Interest Expense InterestExpense	2060068	USD
	us-gaap	Interest Paid InterestPaid	1238400	USD
	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	175000	USD
CY2012Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	377300	USD
CY2012Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	128806060	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	155327780	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36446644	USD
CY2012Q3	us-gaap	Liabilities Current LiabilitiesCurrent	50435274	USD
CY2011Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	33937292	USD
	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	2258852	USD
	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	154700	USD
	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	235700	USD
CY2011Q4	us-gaap	Inventory Net InventoryNet	647745	USD
CY2012Q3	us-gaap	Inventory Net InventoryNet	448045	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	5471166	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	8164814	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1225500	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1376100	USD
CY2011Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	434600	USD
CY2012Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	21943186	USD
CY2012Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	39343867	USD
CY2011Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	28165010	USD
CY2011Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	26388976	USD
CY2012Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	14279651	USD
CY2011Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2012Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	48317	USD
CY2011Q4	us-gaap	Minority Interest MinorityInterest	18106961	USD
CY2012Q3	us-gaap	Minority Interest MinorityInterest	5496475	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">The Business</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem, Inc. (“NeoStem” or the “Company”) was incorporated under the laws of the State of Delaware in September 1980 under the name Fidelity Medical Services, Inc. The Company’s corporate headquarters are located at 420 Lexington Avenue, Suite 350, New York, NY 10170. The Company’s telephone number is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">(212) 584-4180</font><font style="font-family:inherit;font-size:10pt;"> and its website address is </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">www.neostem.com</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is emerging as a technology and market leading company in the fast developing cell therapy industry. The Company's multifaceted business strategy combines a state-of-the-art contract development and manufacturing organization (CDMO) with a medically important cell therapy product development program enabling short-term and long-term revenue growth opportunities. The Company's service business and pipeline of proprietary cell therapy products work in concert, giving the Company a competitive advantage that it believes is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a strategic and growing patent and patent pending (IP) portfolio, the Company is well positioned to succeed.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a leading cell therapy Company, we have  a pipeline of proprietary products, including stem cell therapies for cardiovascular disease and regenerative medicine as well as a T cell therapy for autoimmune disorders.   Through its GMP facilities, NeoStem further supports the cell therapy community’s efforts to discover solutions for chronic disease by providing contract development and manufacturing expertise. In addition, NeoStem offers adult stem cell collection, processing and storage services in the U.S., enabling healthy individuals to donate and store their stem cells for personal therapeutic use.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2011, the Company operated its business in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three reportable segments</font><font style="font-family:inherit;font-size:10pt;">: (i) Cell Therapy — United States; (ii) Regenerative Medicine — China; and (iii) Pharmaceutical Manufacturing — China. In 2012, the Company began to exit its operations in China. Effective March 31, 2012, the Company no longer operated in the Regenerative Medicine – China reportable segment, which is now reported in discontinued operations (see Note 13). On June 18, 2012, the Company signed a definitive agreement to sell its </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">51%</font><font style="font-family:inherit;font-size:10pt;"> interest in Suzhou Erye, which represented the operations in our Pharmaceutical Manufacturing - China segment, and is also reported in discontinued operations (see Note 13). The Erye divestiture closed on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">November 13, 2012</font><font style="font-family:inherit;font-size:10pt;"> (see Note 16). As a result, the Company currently operates in a single reporting segment - Cell Therapy, which will focus on CDMO and cell therapy development programs. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2012</font><font style="font-family:inherit;font-size:10pt;"> and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2011</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2010</font><font style="font-family:inherit;font-size:10pt;"> included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2011</font><font style="font-family:inherit;font-size:10pt;">, as recast in our Current Report on Form 8-K filed with the SEC on August 15, 2012 to reflect our Pharmaceutical Manufacturing - China and Regenerative Medicine - China segments as discontinued operations. Operating results for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2012</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the year ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2012</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of NeoStem, Inc. and its wholly owned and partially owned subsidiaries and affiliates as listed below:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="32%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="25%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Entity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percentage of Ownership</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Location</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Parent  Company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem Therapies, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stem Cell Technologies, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amorcyte, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CBH Acquisition LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">China Biopharmaceuticals Holdings, Inc. (CBH)  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100% owned by CBH Acquisition LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Suzhou Erye Pharmaceuticals Company Ltd. (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51% owned by CBH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">People’s Republic of China</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Progenitor Cell Therapy, LLC (PCT)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem Family Storage, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100% owned by PCT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Athelos Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80.1% owned by PCT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PCT Allendale, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100% owned by PCT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Represents the operations of our former Pharmaceutical Manufacturing - China reporting segment, which was discontinued on June 18, 2012, and is currently reported in discontinued operations. The Erye divestiture closed on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">November 13, 2012</font><font style="font-family:inherit;font-size:10pt;"> (see Note 16).</font></div></div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16516524	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10422534	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	15620864	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	17907165	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2688108	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3127902	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-279593	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	2530423	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4227631	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17522431	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15960427	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16395830	USD
	us-gaap	Net Income Loss NetIncomeLoss	-28287815	USD
CY2011Q3	us-gaap	Net Income Loss NetIncomeLoss	-7346435	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-8410909	USD
	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	0	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	56850	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-38264381	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9490925	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-39540632	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28795885	USD
CY2011Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7497090	USD
	us-gaap	Noncash Contribution Expense NoncashContributionExpense	607363	USD
	us-gaap	Noncash Contribution Expense NoncashContributionExpense	0	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-487261	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1322263	USD
CY2012Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-459049	USD
CY2011Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	660074	USD
CY2012Q3	us-gaap	Notes Payable NotesPayable	183500	USD
CY2011Q4	us-gaap	Notes Payable NotesPayable	148100	USD
CY2012Q3	us-gaap	Notes Payable Current NotesPayableCurrent	135222	USD
CY2011Q4	us-gaap	Notes Payable Current NotesPayableCurrent	148062	USD
	us-gaap	Operating Expenses OperatingExpenses	26950261	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	8775474	USD
CY2011Q3	us-gaap	Operating Expenses OperatingExpenses	7516129	USD
	us-gaap	Operating Expenses OperatingExpenses	24582495	USD
CY2011Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7230450	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22442897	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8089003	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26449362	USD
CY2012Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	4195700	USD
CY2012Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	410800	USD
CY2012Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	563900	USD
CY2012Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	739200	USD
CY2012Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	962100	USD
CY2012Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1226500	USD
CY2012Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	293200	USD
CY2011Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	47427300	USD
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3326938	USD
CY2012Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	932474	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Period Increase Decrease OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease	147301	USD
CY2012Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-50128	USD
CY2011Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	2134363	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	317294	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	2222569	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Period Increase Decrease OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease	-50128	USD
CY2011Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Period Increase Decrease OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease	2134363	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Period Increase Decrease OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease	147301	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Period Increase Decrease OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease	2222569	USD
CY2011Q3	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	-169993	USD
CY2012Q3	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	0	USD
CY2012Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	139276	USD
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2012Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-74881	USD
CY2012Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2728000	USD
CY2011Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1572807	USD
CY2011Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1292911	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	506783	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	197577	USD
CY2012Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	67197	USD
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	508070	USD
CY2011Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	150655	USD
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	263432	USD
CY2011Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	150655	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	508070	USD
CY2012Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	67197	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	263432	USD
CY2012Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2010Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2012Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2012Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2012Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue	100	USD
CY2012Q3	us-gaap	Preferred Stock Value PreferredStockValue	100	USD
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	649739	USD
CY2012Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3228775	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	2728000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	21167682	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	12160227	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	149766	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	223433	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7100	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	5925931	USD
CY2012Q3	us-gaap	Profit Loss ProfitLoss	-8395957	USD
	us-gaap	Profit Loss ProfitLoss	-27728736	USD
CY2011Q3	us-gaap	Profit Loss ProfitLoss	-7328464	USD
	us-gaap	Profit Loss ProfitLoss	-51025744	USD
CY2012Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11067570	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11616053	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	132891	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	187956	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	3000000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	141353	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	109492	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7490002	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2828210	USD
CY2011Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1540441	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5656875	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1150000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-143094854	USD
CY2012Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-181622667	USD
CY2012Q3	us-gaap	Revenues Revenues	4433961	USD
	us-gaap	Revenues Revenues	11578783	USD
CY2011Q3	us-gaap	Revenues Revenues	2177013	USD
	us-gaap	Revenues Revenues	5836978	USD
CY2010Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.945
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	48209993	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	80132518	USD
CY2012Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	53706468	USD
CY2012Q3	nbs	Base Monthly Rent Expense Of Executive Offices BaseMonthlyRentExpenseOfExecutiveOffices	27000	USD
CY2012Q3	nbs	Base Monthly Rent Expense Of Subleases BaseMonthlyRentExpenseOfSubleases	7500	USD
CY2011Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	3635061	USD
CY2012Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	3493708	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21293386	USD
CY2011Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5975688	USD
CY2012Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5947264	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17092493	USD
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	2649236	shares
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12160227	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5471166	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	62025557	USD
	nbs	Clinical Services Reimbursement ClinicalServicesReimbursement	1800000	USD
CY2011Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	6662748	shares
CY2012Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	3135411	shares
CY2012Q3	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	2721132	USD
CY2011Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	4811326	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1661049	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	46910	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits Resulting In Net Operating Loss Carryforward UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward	8838200	USD
CY2012Q2	nbs	Adjusted Conversion Price AdjustedConversionPrice	1.18
CY2012Q3	nbs	Annual Appropriation Percent AnnualAppropriationPercent	0.1
CY2012Q3	nbs	Bank Deposit Freeze BankDepositFreeze	50000000	CNY
	nbs	Clinical Services Reimbursement ClinicalServicesReimbursement	2900000	USD
CY2012Q3	nbs	Preferred Stock Pre Payment Minimum Increment Value PreferredStockPrePaymentMinimumIncrementValue	1000000	USD
	nbs	Preferred Stock Pre Payment Option Minimum Number Of Days Notice To Pre Pay PreferredStockPrePaymentOptionMinimumNumberOfDaysNoticeToPrePay	P30D
	nbs	Preferred Stock Pre Payment Option Percent Of Outstanding Balance PreferredStockPrePaymentOptionPercentOfOutstandingBalance	1.1
CY2011Q4	us-gaap	Temporary Equity Liquidation Preference Per Share TemporaryEquityLiquidationPreferencePerShare	1.00
CY2012Q3	us-gaap	Temporary Equity Liquidation Preference Per Share TemporaryEquityLiquidationPreferencePerShare	1.00
CY2011Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10582011	shares
CY2012Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10582011	shares
CY2012Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	3135411	shares
CY2011Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	6662748	shares
CY2012Q3	nbs	Clinical Services Reimbursement ClinicalServicesReimbursement	900000	USD
CY2011Q3	nbs	Clinical Services Reimbursement ClinicalServicesReimbursement	700000	USD
	nbs	Common Stock Issued To Acquire Businesses CommonStockIssuedToAcquireBusinesses	0	USD
	nbs	Common Stock Issued To Acquire Businesses CommonStockIssuedToAcquireBusinesses	17200000	USD
	nbs	Dividend On Preferred Stock Shares Of Common Stock Issuable DividendOnPreferredStockSharesOfCommonStockIssuable	175700	USD
	nbs	Dividend On Preferred Stock Shares Of Common Stock Issuable DividendOnPreferredStockSharesOfCommonStockIssuable	622500	USD
	nbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	711997	USD
	nbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-46418	USD
	nbs	Issuance Of Common Stock In Connection With Preferred Stock Settlement Value IssuanceOfCommonStockInConnectionWithPreferredStockSettlementValue	938785	USD
	nbs	Issuance Of Common Stock In Exchange For Convertible Preferred Stock IssuanceOfCommonStockInExchangeForConvertiblePreferredStock	2785400	USD
	nbs	Issuance Of Common Stock In Exchange For Convertible Preferred Stock IssuanceOfCommonStockInExchangeForConvertiblePreferredStock	1026600	USD
CY2012Q2	nbs	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2012Q2	nbs	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	nbs	Payment For Warrant Inducement PaymentForWarrantInducement	0	USD
	nbs	Payment For Warrant Inducement PaymentForWarrantInducement	43716	USD
CY2009Q4	nbs	Percentage Of Additional Paid In Capital PercentageOfAdditionalPaidInCapital	0.45
CY2009Q4	nbs	Percentage Of Distributed Profit PercentageOfDistributedProfit	0.06
CY2012Q3	nbs	Percentage Of Registered Capital PercentageOfRegisteredCapital	0.5
CY2009Q4	nbs	Percentage Of Undistributed Profit PercentageOfUndistributedProfit	0.49
CY2010Q4	nbs	Preferred Offering Maximum Period Of Escrow Of Proceeds PreferredOfferingMaximumPeriodOfEscrowOfProceeds	P2Y6M
CY2010Q4	nbs	Preferred Offering Units PreferredOfferingUnits	10582011	shares
CY2012Q2	nbs	Preferred Stock Conversion Conversion Price Per Share PreferredStockConversionConversionPricePerShare	2.0004
CY2012Q3	nbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
CY2011Q4	nbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
	nbs	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	-328003	USD
	nbs	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	-59538	USD
	nbs	Revene Recognition Period For Cryoperservation Process ReveneRecognitionPeriodForCryoperservationProcess	PT24H
	nbs	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	5925931	USD
	nbs	Stock Issued During Period Value Warrant Inducements StockIssuedDuringPeriodValueWarrantInducements	-43716	USD
	nbs	Supplemental Dividends From Subsidiaries SupplementalDividendsFromSubsidiaries	0	USD
	nbs	Supplemental Dividends From Subsidiaries SupplementalDividendsFromSubsidiaries	11726100	USD
	nbs	Warrant Inducements WarrantInducements	1012819	USD
CY2012Q3	nbs	Warrant Inducements WarrantInducements	1012819	USD
	nbs	Warrant Inducements WarrantInducements	0	USD
CY2011Q3	nbs	Warrant Inducements WarrantInducements	0	USD
	nbs	Weightedaveragenumberbasicdilutedsharesoutstanding Weightedaveragenumberbasicdilutedsharesoutstanding	131533057	shares
CY2012Q3	nbs	Weightedaveragenumberbasicdilutedsharesoutstanding Weightedaveragenumberbasicdilutedsharesoutstanding	148197077	shares
	nbs	Weightedaveragenumberbasicdilutedsharesoutstanding Weightedaveragenumberbasicdilutedsharesoutstanding	82775215	shares
CY2011Q3	nbs	Weightedaveragenumberbasicdilutedsharesoutstanding Weightedaveragenumberbasicdilutedsharesoutstanding	94102589	shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
	dei	Document Period End Date DocumentPeriodEndDate	2012-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000320017
CY2012Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	159414582	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	NeoStem, Inc.

Files In Submission

Name	View Source	Status
0000320017-12-000019-index-headers.html	Edgar Link	pending
0000320017-12-000019-index.html	Edgar Link	pending
0000320017-12-000019.txt	Edgar Link	pending
0000320017-12-000019-xbrl.zip	Edgar Link	pending
exhibit101formofsubscripti.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
nbs-10qx20120930.htm	Edgar Link	pending
nbs-20120930.xml	Edgar Link	completed
nbs-20120930.xsd	Edgar Link	pending
nbs-20120930_cal.xml	Edgar Link	unprocessable
nbs-20120930_def.xml	Edgar Link	unprocessable
nbs-20120930_lab.xml	Edgar Link	unprocessable
nbs-20120930_pre.xml	Edgar Link	unprocessable
nbs-ex311_20120930xq2.htm	Edgar Link	pending
nbs-ex312_20120930xq2.htm	Edgar Link	pending
nbs-ex321_20120930xq2.htm	Edgar Link	pending
nbs-ex322_20120930xq2.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

2012 Q4 Form 10-Q Financial Statement

#000032001712000019 Filed on November 13, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA LISATA THERAPEUTICS, INC. Stock $lsta

2012 Q4 Form 10-Q Financial Statement

#000032001712000019 Filed on November 13, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta